Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alternative Antithrombotic Pathways in Acute STEMI With Large Coronary Thrombus Burden
2020-005156-38Phase 4Terminated
- Sponsor
- Azienda Ospedaliero-Universitaria Maggiore della Carità
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of rivaroxaban, ticagrelor and clopidogrel in myocardial infarction (MI) (4 arms), sponsored by Azienda Ospedaliero-Universitaria Maggiore della Carità. Primary endpoint: Change in thrombus burden and thrombus volume. Started Jun 2021; status: terminated.
02
Drugs
rivaroxabanticagrelorclopidogrel
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on 2020-005156-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005156-38.